Who
William W. Ericson
Director
Company insider
Files Form 4 as: Director, Pacific Biosciences of California; Director and 10% owner, Adamas Pharmaceuticals; Director and 10% owner, Rocket Fuel; 10% owner, Rally Software Development.
In numbers
- Trades disclosed
- 118
- Buys
- 21
- Sells
- 15
- Bought
- $13.8M
- Sold
- $152.7M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 26 Oct 2010
- Last trade
- 3 Jun 2026
- Last filed
- 4 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 4 Jun 2026 | PACB Pacific Biosciences of Californiaoption or derivative · Life-science tools | SEC FORM 4 Code A | —223,492 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | PACB Pacific Biosciences of Californiaoption or derivative · Life-science tools | SEC FORM 4 Code A | —223,492 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | PACB Pacific Biosciences of Californiaoption or derivative · Life-science tools | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | PACB Pacific Biosciences of Californiaoption or derivative · Life-science tools | SEC FORM 4 Code A | —32,179 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | PACB Pacific Biosciences of CaliforniaLife-science tools | SEC FORM 4 Code A | —22,821 at $0.00 | filing |
| 24 May 2023filed 26 May 2023 | PACB Pacific Biosciences of Californiaoption or derivative · Life-science tools | SEC FORM 4 Code A | —25,775 at $0.00 | filing |
| 15 Mar 2023filed 17 Mar 2023 | PACB Pacific Biosciences of Californiaoption or derivative · Life-science tools | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 15 Mar 2023filed 17 Mar 2023 | PACB Pacific Biosciences of CaliforniaLife-science tools | SEC FORM 4 Code M | $64K25,000 at $2.54 | filing |
| 15 Mar 2023filed 17 Mar 2023 | PACB Pacific Biosciences of CaliforniaLife-science tools | SEC FORM 4 Sold | $67K7,541 at $8.90 | filing |
| 25 May 2022filed 27 May 2022 | PACB Pacific Biosciences of Californiaoption or derivative · Life-science tools | SEC FORM 4 Code A | —63,015 at $0.00 | filing |
| 17 Mar 2022filed 13 Apr 2022 | PACB Pacific Biosciences of CaliforniaLife-science tools | SEC FORM 4 Code J | —4,848,397 | filing |
| 17 Mar 2022filed 13 Apr 2022 | PACB Pacific Biosciences of CaliforniaLife-science tools | SEC FORM 4 Code J | —1,268 | filing |
| 24 Nov 2021filed 24 Nov 2021 | Adamas Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 24 Nov 2021filed 24 Nov 2021 | Adamas Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 24 Nov 2021filed 24 Nov 2021 | Adamas Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 24 Nov 2021filed 24 Nov 2021 | Adamas Pharmaceuticals | SEC FORM 4 Code U | —10,000 | filing |
| 24 Nov 2021filed 24 Nov 2021 | Adamas Pharmaceuticals | SEC FORM 4 Code U | —4,031,804 | filing |
| 24 Nov 2021filed 24 Nov 2021 | Adamas Pharmaceuticals | SEC FORM 4 Code U | —6,043 | filing |
| 24 Nov 2021filed 24 Nov 2021 | Adamas Pharmaceuticals | SEC FORM 4 Code U | —3,146 | filing |
| 24 Nov 2021filed 24 Nov 2021 | Adamas Pharmaceuticals | SEC FORM 4 Code U | —25,661 | filing |
News
Head-To-Head Analysis: Pacific Biosciences of California (NASDAQ:PACB) & Simulations Plus (NASDAQ:SLP)PACB · tickerreport.com · 21 Oct 2026
0 headlines in the last 90 days name William W. Ericson; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.